GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sarepta Therapeutics Inc (NAS:SRPT) » Definitions » Shiller PE Ratio

Sarepta Therapeutics (Sarepta Therapeutics) Shiller PE Ratio : (As of Jun. 10, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Sarepta Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Sarepta Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Sarepta Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sarepta Therapeutics Shiller PE Ratio Chart

Sarepta Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sarepta Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sarepta Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Sarepta Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sarepta Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Sarepta Therapeutics's Shiller PE Ratio falls into.



Sarepta Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Sarepta Therapeutics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Sarepta Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.37/131.7762*131.7762
=0.370

Current CPI (Mar. 2024) = 131.7762.

Sarepta Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.850 100.560 -1.114
201409 -0.710 100.428 -0.932
201412 -1.080 99.070 -1.437
201503 -1.490 99.621 -1.971
201506 -1.010 100.684 -1.322
201509 -1.250 100.392 -1.641
201512 -1.440 99.792 -1.902
201603 -1.310 100.470 -1.718
201606 -1.350 101.688 -1.749
201609 -1.180 101.861 -1.527
201612 -1.620 101.863 -2.096
201703 1.500 102.862 1.922
201706 -1.150 103.349 -1.466
201709 -0.780 104.136 -0.987
201712 -0.370 104.011 -0.469
201803 -0.550 105.290 -0.688
201806 -1.670 106.317 -2.070
201809 -1.150 106.507 -1.423
201812 -2.052 105.998 -2.551
201903 -1.070 107.251 -1.315
201906 -3.740 108.070 -4.560
201909 -1.700 108.329 -2.068
201912 -3.170 108.420 -3.853
202003 -0.230 108.902 -0.278
202006 -1.930 108.767 -2.338
202009 -2.500 109.815 -3.000
202012 -2.410 109.897 -2.890
202103 -2.100 111.754 -2.476
202106 -1.020 114.631 -1.173
202109 -0.600 115.734 -0.683
202112 -1.430 117.630 -1.602
202203 -1.200 121.301 -1.304
202206 -2.650 125.017 -2.793
202209 -2.940 125.227 -3.094
202212 -1.240 125.222 -1.305
202303 -5.860 127.348 -6.064
202306 -0.270 128.729 -0.276
202309 -0.460 129.860 -0.467
202312 0.760 129.419 0.774
202403 0.370 131.776 0.370

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sarepta Therapeutics  (NAS:SRPT) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Sarepta Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Sarepta Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sarepta Therapeutics (Sarepta Therapeutics) Business Description

Traded in Other Exchanges
Address
215 First Street, Suite 415, Cambridge, MA, USA, 02142
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.
Executives
Richard Barry director 285 MARGALITA DRIVE, SAN RAFAEL CA 94901
Douglas S Ingram director, officer: President & CEO 2525 DUPONT DR, IRVINE CA 92612
Michael Andrew Chambers director 215 FIRST STREET, CAMBRIDGE MA 02142
Wigzell Hans Lennart Rudolf director OSKAR BAECKSTROMSV.11, HAGERSTEN V7 12935
Bilal Arif officer: Chief Tech Ops Officer 215 FIRST STREET, CAMBRIDGE MA 02129
Stephen Mayo director 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Kathryn Jean Boor director 3736 S. MAIN STREET, MARION NY 14505
Louise Rodino-klapac officer: Chief Scientific Officer 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
M Kathleen Behrens director 6701 KAISER DRIVE, FREMONT CA 94555
Ryan Edward Brown officer: SVP, General Counsel 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
Ian Michael Estepan officer: Chief Financial Officer 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
Joseph Bratica officer: Principal Financial Officer 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
David T Howton officer: SVP, General Counsel VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
John C Martin director 333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Sandesh Mahatme officer: Senior Vice President, CFO C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901